TCRX Q4 2023 Earnings — TScan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TCRXTScan Therapeutics, Inc.

$69M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+133.0% YoY

Gross Profit

$6M82.2% margin

Operating Income

-$21M-296.2% margin

Net Income

-$20M-272.0% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

+85.5%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$24M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$272M

Total Liabilities

$121M

Stockholders' Equity

$151M

Cash & Equivalents

$133M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$3M	+133.0%
Gross Profit	$6M	$2M	+268.2%
Operating Income	-$21M	-$19M	-14.5%
Net Income	-$20M	-$19M	-4.8%